Alnylam Obtains Rights to RNAi Delivery Technology from The CBR Institute

11-May-2006

Alnylam Pharmaceuticals, Inc. announced that it has obtained rights to RNAi delivery technology developed in the laboratory of Professor Judy Lieberman from the CBR Institute for Biomedical Research, a Harvard Medical School Affiliate. The in-licensed technology may enable small interfering RNAs - or siRNAs, the molecules that mediate RNAi - to be targeted with an engineered monoclonal antibody to tumors and other cell types, thereby broadening the scope of Alnylam's delivery technologies for RNAi therapeutics. The in-licensed technology represents another potential approach for delivery of RNAi therapeutics with systemic administration.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances